Motexafin gadolinium
- Generic Name
- Motexafin gadolinium
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C52H72GdN5O14
- CAS Number
- 246252-06-2
- Unique Ingredient Identifier
- 0BG5NE3APZ
- Background
Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to the family of drugs called metalloporphyrin complexes. Also called gadolinium texaphyrin.
- Indication
Investigated for use/treatment in brain cancer, cancer/tumors (unspecified), lung cancer, and lymphoma (non-hodgkin's).
- Associated Conditions
- -
- Associated Therapies
- -
Motexafin Gadolinium and Radiation Therapy in Treating Young Patients With Pontine Glioma
- Conditions
- Untreated Childhood Brain Stem Glioma
- Interventions
- Drug: motexafin gadoliniumRadiation: 3-dimensional conformal radiation therapy
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 64
- Registration Number
- NCT00387790
- Locations
- 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- Conditions
- Adult GlioblastomaAdult GliosarcomaAdult Giant Cell Glioblastoma
- Interventions
- First Posted Date
- 2006-03-22
- Last Posted Date
- 2018-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 118
- Registration Number
- NCT00305864
- Locations
- 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
- Conditions
- Stage IIIA Non-small Cell Lung Cancer
- Interventions
- Drug: paclitaxelDrug: carboplatinDrug: motexafin gadoliniumProcedure: conventional surgeryRadiation: radiation therapy
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00005065
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
- Interventions
- Procedure: conventional surgeryRadiation: 3-dimensional conformal radiation therapyRadiation: stereotactic radiosurgeryDrug: motexafin gadoliniumProcedure: magnetic resonance imagingProcedure: spectroscopy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT00004262
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
- Conditions
- Untreated Childhood Brain Stem Glioma
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00003909
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Motexafin Gadolinium in Treating Patients With Glioblastoma Multiforme Who Are Undergoing Radiation Therapy to the Brain
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00032097
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.